Gepotidacin is a first-in-class triazaacenaphthylene antibiotic with a novel mechanism, inhibiting bacterial DNA replication at a distinct binding site. Phase 3 trials EAGLE-2 and EAGLE-3 showed ...

In a recent long-term, multicenter analysis of patients undergoing robot-assisted radical cystectomy, the 12-year overall survival for the entire cohort was 49%, whereas the cancer-specific survival ...

"I think [gepotidacin] gives a different side effect profile available to the clinicians, and I think for patients as well, it provides a better, more durable option over time," says Ryan Haumschild, ...

"A lot of times…decreased desire is affected by everything else: pain with sex, orgasm, arousal. Because if none of that is good, then desire isn't going to be good either," says Anna Myers, CNP. In a ...

An expert discusses how TAR-200 shows promise for non–muscle invasive bladder cancer (NMIBC) treatment, with medical professionals optimistic about its targeted delivery, potentially improved outcomes ...

Durvalumab addition improved overall and event-free survival without affecting radical cystectomy rates or surgical complications in muscle-invasive bladder cancer. Surgical outcomes and ...

Aquablation and LEP provide similar short-term symptom relief for BPH, with Aquablation showing lower ejaculatory dysfunction and stress incontinence rates. LEP offers superior prostate volume ...

Michael R. Folkert, MD, PhD, discusses real-world outcomes with spacer in prostate cancer ...

The phase 2 STARLITE 2 trial is assessing 177Lu-girentuximab plus nivolumab in advanced clear cell renal cell carcinoma. The phase 2 STARLITE 2 trial (NCT05239533) is assessing the safety and efficacy ...

Isodose MHFRT shows similar efficacy to CFRT without increased urinary or bowel toxicity, supporting its use as a standard care regimen. Dose-escalated MHFRT is associated with higher odds of bowel ...

“I think we can really use AI in several different facets of endourology," says Perry Xu, MD. In a recent interview with Urology Times®, Perry Xu, MD, spoke about artificial intelligence’s potential ...

“For all intents and purposes, how you've been practicing telehealth currently is exactly how you'll be able to practice it until September 30," says Chad Ellimoottil, MD, MS. Last week Congress ...